Clinical Trial Update: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application [Phase 1, Phase 2]

View source ↗

Summary

This entry reports a Phase 1/2 clinical trial of Lu-177 Ludotadipep for metastatic castration-resistant prostate cancer, with ongoing recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lu-177 Ludotadipep (Lutetium-177-ludotadipep)

Snippet

Sponsor: FutureChem | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING